VCYT

Veracyte, Inc. develops and commercializes genomic tests for cancer diagnosis and treatment decision-making. Its product offerings include tests for thyroid, prostate, breast, bladder, and lung cancers, which assess the unique biology of each patient's tumor to enable personalized care. The company operates a diagnostics platform that generates evidence to support the clinical utility of its tests, serving healthcare providers and patients primarily in the United States.